Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials

United Nations. Contraceptive use by method. 2019. Available at: https://digitallibrary.un.org/record/3849735?ln=en (accessed June 27, 2022). Kavanaugh, 2020, Use of contraception among reproductive-aged women in the United States, 2014 and 2016, F S Rep, 1, 83 Bitzer, 2011, Current issues and available options in combined hormonal contraception, Contraception, 84, 342, 10.1016/j.contraception.2011.02.013 Both, 2019, Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM), J Sex Med, 16, 1681, 10.1016/j.jsxm.2019.08.005 Lundin, 2021, Towards individualized contraceptive counselling: clinical and reproductive factors associated with self-reported hormonal contraceptive-induced adverse mood symptoms, BMJ Sex Reprod Health, 10.1136/bmjsrh-2020-200658 Lawrie, 2011, Types of progestogens in combined oral contraception: effectiveness and side-effects, Cochrane Database Syst Rev, 10.1002/14651858.CD004861.pub2 Gallo, 2014, Combination contraceptives: effects on weight, Cochrane Database Syst Rev, 10.1002/14651858.CD003987.pub5 Villavicencio, 2016, Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates, Open Access J Contracept, 7, 43 Dragoman, 2018, A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception, Int J Gynaecol Obstet, 141, 287, 10.1002/ijgo.12455 Oedingen, 2018, Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose, Thromb Res, 165, 68, 10.1016/j.thromres.2018.03.005 Vinogradova, 2015, Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases, BMJ, 350, h2135, 10.1136/bmj.h2135 Alspaugh, 2020, Women's Contraceptive Perceptions, Beliefs, and Attitudes: An Integrative Review of Qualitative Research, J Midwifery & Women's Health, 65, 64, 10.1111/jmwh.12992 Grossman, 2010, Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas, Contraception, 81, 254, 10.1016/j.contraception.2009.09.009 Simmons, 2019, Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants, Am J Obstet Gynecol, 220, e1 Westhoff, 2007, Oral contraceptive discontinuation: do side effects matter?, Am J Obstetrics and Gynecol, 196, e1 Abot, 2014, The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation, EMBO Mol Med, 6, 1328, 10.15252/emmm.201404112 Arnal, 2017, Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications, Physiol Rev, 97, 1045, 10.1152/physrev.00024.2016 Foidart, 2019, Estetrol (E4) Is a Unique Estrogen with Selective Actions in Tissues Which Are Distinctly Different from the Actions of SERMs, J Endocrine Soc, 3, 10.1210/js.2019-SUN-LB001 Guivarc'h, 2018, Predominant role of nuclear versus membrane estrogen receptor alpha in arterial protection: implications for estrogen receptor alpha modulation in cardiovascular prevention/safety, J Am Heart Assoc, 7, 10.1161/JAHA.118.008950 Douxfils, 2020, Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters, Contraception, 102, 396, 10.1016/j.contraception.2020.08.015 Gérard, 2015, Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation, J Endocrinol, 224, 85, 10.1530/JOE-14-0549 Klipping, 2021, Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone, Contraception, 103, 213, 10.1016/j.contraception.2021.01.001 Kluft, 2017, Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol, Contraception, 95, 140, 10.1016/j.contraception.2016.08.018 Mawet, 2015, Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives, Eur J Contracept Reprod Health Care, 20, 463 Creinin, 2021, Estetrol-Drospirenone Combination Oral Contraceptive: North American Phase 3 Efficacy and Safety Results, Contraception, 10.1016/j.contraception.2021.05.002 Gemzell-Danielsson, 2021, Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern, and safety in Europe and Russia, BJOG Kapp, 2007, Study design to evaluate the safety and effectiveness of hormonal contraception for women, Clin Obstet Gynecol, 50, 850, 10.1097/GRF.0b013e318159bf8a Grossman Barr, 2010, Managing adverse effects of hormonal contraceptives, Am Fam Physician, 82, 1499 Lidegaard, 2011, Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9, BMJ, 343, d6423, 10.1136/bmj.d6423 Heinemann, 2007, Range of published estimates of venous thromboembolism incidence in young women, Contraception, 75, 32836, 10.1016/j.contraception.2006.12.018 European Medicines Agency. Drovelis (estetrol /drospirenone): EPAR - public assessment report. 2021. Available at: https://www.ema.europa.eu/en/documents/assessment-report/drovelis-epar-public-assessment-report_en.pdf (accessed June 27, 2022) Suissa, 1997, First-time use of newer oral contraceptives and the risk of venous thromboembolism, Contraception, 56, 141, 10.1016/S0010-7824(97)00119-4 Gomes, 2004, Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review, Archives of Internal Medicine, 164, 1965, 10.1001/archinte.164.18.1965 Han, 2015, Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?, Obstet Gynecol Clin North Am, 42, 683, 10.1016/j.ogc.2015.07.007 Suissa, 2000, Recurrent use of newer oral contraceptives and the risk of venous thromboembolism, Hum Reprod, 15, 817, 10.1093/humrep/15.4.817 Portman, 2014, Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive, Contraception, 89, 299, 10.1016/j.contraception.2014.01.013 Kroll, 2016, Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol, Contraception, 93, 249, 10.1016/j.contraception.2015.10.007 Coelingh Bennink, 2017, Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study, Menopause, 24, 677, 10.1097/GME.0000000000000823 NEXTSTELLIS. Prescibing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf (accessed June 27, 2022). Drovelis (estetrol /drospirenone). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/drovelis (accessed June 27, 2022).